Low on-treatment levels of serum soluble cd8 (scd8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab

HIGHLIGHTS

• who: Anna Siemiu0105tkowska from the Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, Rokietnicka Street, u2011806, Poznau0144, Poland have published the research work: Low on-treatment levels of serum soluble CD8 (sCD8) predict better outcomes in advanced non-small cell lung cancer patients treated with atezolizumab, in the Journal: (JOURNAL)
• what: The focus of the study was to assess the usefulness of circulating sCD8 as a biomarker of long-term benefits from therapy with immune checkpoint inhibitors. The authors acknowledge that the study had some limitations.
• how: The study was . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.